Analysts forecast that DexCom, Inc. (NASDAQ:DXCM) will announce earnings per share (EPS) of $0.70 for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have issued estimates for DexCom’s earnings, with estimates ranging from $0.38 to $0.88. DexCom reported earnings of $0.54 per share in the same quarter last year, which indicates a positive year over year growth rate of 29.6%. The business is expected to issue its next quarterly earnings report on Thursday, February 20th.
According to Zacks, analysts expect that DexCom will report full year earnings of $1.41 per share for the current fiscal year, with EPS estimates ranging from $1.25 to $1.56. For the next financial year, analysts anticipate that the firm will post earnings of $1.75 per share, with EPS estimates ranging from $1.05 to $2.20. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow DexCom.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.45. The business had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. DexCom’s quarterly revenue was up 48.6% compared to the same quarter last year. During the same period last year, the company posted $0.17 earnings per share.
In other DexCom news, insider Andrew K. Balo sold 9,107 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $151.56, for a total value of $1,380,256.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $185.29, for a total value of $223,830.32. The disclosure for this sale can be found here. Insiders sold a total of 105,222 shares of company stock valued at $16,407,406 in the last quarter. 1.80% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the business. Cortina Asset Management LLC acquired a new position in shares of DexCom in the 2nd quarter worth approximately $263,000. Silverleafe Capital Partners LLC purchased a new position in shares of DexCom during the 2nd quarter worth approximately $474,000. Sanders Morris Harris LLC purchased a new position in shares of DexCom during the 2nd quarter worth approximately $759,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of DexCom during the 2nd quarter worth approximately $479,000. Finally, Chicago Capital LLC grew its holdings in shares of DexCom by 1.2% during the 2nd quarter. Chicago Capital LLC now owns 194,673 shares of the medical device company’s stock worth $29,170,000 after acquiring an additional 2,357 shares during the period. Institutional investors and hedge funds own 96.19% of the company’s stock.
NASDAQ:DXCM opened at $198.08 on Friday. The business has a fifty day simple moving average of $155.57 and a two-hundred day simple moving average of $146.29. The company has a market capitalization of $14.00 billion, a P/E ratio of 660.27 and a beta of 0.64. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. DexCom has a 1 year low of $105.05 and a 1 year high of $200.80.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.